TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22181973
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg letrozole/day for five days combined with intrauterine insemination
Study: 22181973
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg clomiphene citrate/day for five days combined with intrauterine insemination
Study: 18853679
Drug: Clonidine (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.15 mg orally 60 minutes before surgery) and ketamine (20 mg intravenous bolus followed by intraoperative perfusion of 20 mg h(‐1))
Study: 8688997
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg losigamone
Study: 8688997
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg losigamone
Study: 8688997
Drug: 700 mg
Normalized name: cystine 700 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 700 mg losigamone
Study: 8688997
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg losigamone for 6 days (t.i.d.)
Study: 8688997
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg losigamone for 28 days
Study: 8688997
Drug: 1,200 mg
Normalized name: lecithin 1,200 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,200 mg losigamone for 28 days
Study: 8688997
Drug: 1,800 mg
Normalized name: daratumumab-hyaluronidase-fihj 1,800 mg-30,000 unit/15 mL SUBCUT VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,800 mg losigamone for 28 days
Study: 6129370
Drug: hpGRF-40 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: hpGRF-40 (1 microgram/kg bodyweight, administered as an intravenous bolus)
Study: 30786861
Drug: 12-week moderate-intensity
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week moderate-intensity exercise program (Borg perceived rating scale 13-14), at least three times weekly; one supervised group training and two home-based sessions.
Study: 29042662
Drug: Continuing NA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuing NA therapy
Study: 25099775
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of RehaCom cognitive training and acupuncture
Study: 22824097
Drug: DAS‐steered treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAS‐steered treatment (DAS ≤ 2.4)
Study: 15073704
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of milrinone
Study: 15073704
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of milrinone and NO
Study: 11835382
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate (8g/m2)
Study: 7997415
Drug: Prednisone 2
Normalized name: prednisone 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 2 mg/kg/day reducing to zero over 14 days (n = 12)
Study: 18325601
Drug: Levobupivacaine 0.25%
Normalized name: levobupivacaine 0.25% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 0.25% (Group L)
Study: 1729559
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia with EMLA cream applied on one side of the scrotum.
Study: 1729559
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia with EMLA cream applied on one side of the scrotum before bilateral mepivacaine infiltration.
Study: 6710300
Drug: 0.5 per
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 per cent chlorhexidine gluconate spray
Study: 3088636
Drug: Binedaline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Binedaline (50 mg)
Study: 29300925
Drug: Oral micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral micronized progesterone (0.8 mg/kg/dose)
Study: 19927151
Drug: Olmesartan (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan (20 mg day(-1))
Study: 19927151
Drug: Candesartan (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (8 mg day(-1))
Study: 16604818
Drug: IFNbeta‐1b‐G (glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFNbeta‐1b‐G (glucose formulation)
Study: 16604818
Drug: IFNbeta‐1b‐M (refrigeration-free
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFNbeta‐1b‐M (refrigeration-free formulation)
Study: 8851595
Drug: Conventional dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dosing (CD) vancomycin therapy (1 g every 12 h)
Study: 8851595
Drug: Continuous-infusion (CI)
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous-infusion (CI) vancomycin therapy (500 mg loading dose followed by 2 g infused over 24 h)
Study: 1496949
Drug: Somatotropin recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatotropin recombinant DNA (24 IU/m2 of body surface area) subcutaneously administered in six injections per week for 2 years
Study: 1496949
Drug: Somatotropin recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatotropin recombinant DNA (24 IU/m2 of body surface area) subcutaneously administered in three injections per week for 2 years
Study: 6149737
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) benztropine mesylate (2 mg)
Study: 6149737
Drug: Oral benztropine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral benztropine mesylate (2 mg three times a day)
Study: 6149737
Drug: Neuroleptic withdrawal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuroleptic withdrawal (four weeks of dose tapering and six weeks of placebo treatment)
Study: 30403937
Drug: Three-drug regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-drug regimen (ivermectin + diethylcarbamazine + albendazole)
Study: 30403937
Drug: Two-drug regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-drug regimen (diethylcarbamazine + albendazole) - single dose
Study: 30403937
Drug: Two-drug regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-drug regimen (diethylcarbamazine + albendazole) - administered once a year for 3 years
Study: 26718094
Drug: Group Cognitive-Behavioral
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Cognitive-Behavioral Treatment (GCBT)
Study: 25323538
Drug: Sunflower seed
Normalized name: SUNFLOWER SEED
DrugBank: Sunflower seed (DB10907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunflower seed oil (SSO) applied daily during the first 10 postnatal days
Study: 20733134
Drug: Oral midostaurin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral midostaurin at 50 or 100 mg twice daily
Study: 20733134
Drug: Oral midostaurin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral midostaurin at 100 mg twice daily
Study: 20733134
Drug: Oral midostaurin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral midostaurin at 50 mg twice daily
Study: 11753159
Drug: Erythromycin 10
Normalized name: erythromycin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 10 mg/kg, 8 hourly for 7 days
Study: 9848502
Drug: Isolated soy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isolated soy protein containing 1.39 mg isoflavones/g protein (ISP56)
Study: 9848502
Drug: Isolated soy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isolated soy protein containing 2.25 mg isoflavones/g protein (ISP90)
Study: 2754021
Drug: Felodipine treatment
Normalized name: Felodipine
DrugBank: Felodipine (DB01023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Felodipine treatment 10 mg b.i.d. for 8 weeks
Study: 20121
Drug: Air injection
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air injection technique
Study: 29525602
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg aflibercept
Study: 22169831
Drug: Low level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low level laser therapy (3 J) and exercises
Study: 19605849
Drug: Fludarabine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine (25 mg/m² for 5 days intravenously, every 28 days, for 6 courses)
Study: 19605849
Drug: Chlorambucil (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorambucil (0.4 mg/kg body weight with an increase to 0.8 mg/kg, every 15 days, for 12 months)
Study: 8980759
Drug: Doxycycline 100
Normalized name: doxycycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 100 mg orally every 12 h for 45 days + Gentamicin 240 mg intramuscularly once daily for 7 days
Study: 8980759
Drug: Doxycycline at
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline at the same dosage for 30 days + Gentamicin 240 mg intramuscularly once daily for 7 days
Study: 8945276
Drug: Conventional disposable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional disposable syringes with multiple‐ and single‐dose vials
Study: 2886245
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg famotidine at 9 PM only
Study: 28809789
Drug: G-Breakfast
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-Breakfast
Study: 24681850
Drug: Low-dose computed
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose computed tomography (LDCT) with adaptive statistical iterative reconstruction (ASIR) blending ratios (0%, 30%, 50%, and 70%)
Study: 31277780
Drug: Standard-dose computed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose computed tomography (SDCT)
Study: 20921462
Drug: Panitumumab 6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panitumumab 6.0 mg/kg plus FOLFIRI
Study: 18826749
Drug: Travoprost (a.m.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Travoprost (a.m. dosing)
Study: 18826749
Drug: Latanoprost (a.m.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latanoprost (a.m. dosing)
Study: 18826749
Drug: Travoprost (evening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Travoprost (evening dosing)
Study: 18826749
Drug: Latanoprost (evening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latanoprost (evening dosing)
Study: 14585918
Drug: Oral valdecoxib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral valdecoxib 20 mg once daily
Study: 8614068
Drug: Sequential gradient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential gradient intermittent pneumatic compression (SGIPC)
Study: 22321131
Drug: Harm reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Harm reduction focused school drug education program (10 lessons in year eight and 8 lessons in year nine)
Study: 22321131
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving the normal drug education provided in their schools
Study: 17464140
Drug: Slow extended
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow extended daily dialysis (SLEDD)
Study: 12200949
Drug: Clonidine 75
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine 75 micrograms with prilocaine 75 mg
Study: 12200949
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (prilocaine 75 mg alone)
Study: 3397523
Drug: Lofepramine 70
Normalized name: lofepramine 70 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lofepramine 70 mg
Study: 3397523
Drug: Lofepramine 140
Normalized name: lofepramine
DrugBank: Lofepramine (DB13411)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lofepramine 140 mg
Study: 29462482
Drug: Adjuvant S-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant S-1 therapy
Study: 28169983
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (preoperative education and postoperative routine physical therapy)
Study: 26314389
Drug: Budesonide (swallowed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (swallowed topical corticosteroids)
Study: 23127920
Drug: CIDR-G of
Normalized name: Eazi-Breed CIDR
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIDR-G of first use (new devices)
Study: 23127920
Drug: CIDR-G of
Normalized name: Eazi-Breed CIDR
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIDR-G of third use (previously used twice)
Study: 23127920
Drug: CIDR-G of
Normalized name: Eazi-Breed CIDR
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIDR-G of second use (previously used once)
Study: 12697590
Drug: Remifentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil at 2 ng ml(‐1) (low)
Study: 12697590
Drug: Remifentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil at 4 ng ml(‐1) (medium)
Study: 12697590
Drug: Remifentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil at 8 ng ml(‐1) (high)
Study: 2931421
Drug: Procaterol inhaled
Normalized name: procaterol
DrugBank: Procaterol (DB01366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procaterol inhaled (10 micrograms)
Study: 2931421
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered with a pressurized metered-dose inhaler)
Study: 29450636
Drug: Low-dose cyclophosphamide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cyclophosphamide (CYC) 6 × 500 mg fortnightly
Study: 29450636
Drug: High-dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cyclophosphamide (CYC) 6 × 750 mg/m2 four-weekly
Study: 29450636
Drug: High-dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cyclophosphamide (CYC)
Study: 29450636
Drug: Low-dose cyclophosphamide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cyclophosphamide (CYC)
Study: 26826547
Drug: HantavaxTM (three-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: HantavaxTM (three-dose schedule at 0, 1, and 13 months)
Study: 22283848
Drug: Strontium ranelate
Normalized name: Strontium ranelate
DrugBank: Strontium ranelate (DB09267)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Strontium ranelate (4 g day⁻¹ for 15 days)
Study: 22283848
Drug: Moxifloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin (400 mg single dose preceded by 15 days of placebo)
Study: 19575740
Drug: Polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol 3350 (PEG), 3.45 g t.i.d. orally for 30 days
Study: 10361110
Drug: Extended ATRA
Normalized name: ATRA
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extended ATRA (5-day course before chemotherapy)
Study: 10361110
Drug: Extended ATRA
Normalized name: ATRA
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extended ATRA in patients with WBC < 10 x 10(9)/L
Study: 10361110
Drug: RT-PCR monitoring
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT-PCR monitoring after third chemotherapy course
Study: 28705210
Drug: Transcutaneous electrical
Normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous electrical stimulation of the foot for 60 minutes daily for 3 days after surgery
Study: 16986228
Drug: Valsartan 160
Normalized name: valsartan 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 160 mg plus HCTZ 25 mg once daily
Study: 30772975
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose group (300 mg clopidogrel)
Study: 30772975
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose group (75 mg clopidogrel)
Study: 30772975
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose group (CYP2C19*2 carriers)
Study: 30772975
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose group (CYP2C19*2 carriers)
Study: 29995359
Drug: Tianeptine 25-50
Normalized name: tianeptine
DrugBank: Tianeptine (DB09289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tianeptine 25-50 mg/d
Study: 26893309
Drug: Soft tissue
Normalized name: INSULIN DETEMIR 14.2 mg in 1 mL SOFT TISSUE IMPLANT [Levemir]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft tissue treatment (Astym) and eccentric exercise
Study: 19875236
Drug: Subcutaneous pedicle
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous pedicle island flap
Study: 15750362
Drug: Qigong lessons
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qigong lessons for 20 minutes at least twice weekly over a period of 6 months
Study: 12150309
Drug: Fixed-dose warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose warfarin
Study: 10215274
Drug: Prior aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prior aspirin use
Study: 8530644
Drug: Gonadotrophin-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotrophin-releasing hormone agonist (GnRHa, triptorelin) 0.1 mg s.c. injection
Study: 8530644
Drug: Human chorionic
Normalized name: human chorionic gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human chorionic gonadotrophin (HCG) 10,000 IU i.m. injection
Study: 320109
Drug: D-penicillamine (1-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-penicillamine (1-2 g daily)
Study: 320109
Drug: Prednisone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (15 mg daily)
Study: 26669544
Drug: External Connection
Approvals — FDA: no, EMA: no, PMDA: no
Description: External Connection (EC) implants
Study: 26669544
Drug: Internal Connection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internal Connection (IC) implants
Study: 23115085
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of rifampicin (600 mg)
Study: 23115085
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of rifampicin (600 mg)
Study: 18258749
Drug: Licabazepine 500
Normalized name: Eslicarbazepine
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licabazepine 500 mg single dose
Study: 18258749
Drug: Licabazepine 500
Normalized name: Eslicarbazepine
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licabazepine 500 mg multiple doses (500 mg bid on days 3 to 6)
Study: 18258749
Drug: Licabazepine 500
Normalized name: Eslicarbazepine
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licabazepine 500 mg single dose under fasted conditions
Study: 18258749
Drug: Licabazepine 500
Normalized name: Eslicarbazepine
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licabazepine 500 mg single dose under fed conditions
Study: 16239861
Drug: Group cognitive-behavioral
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive-behavioral therapy (GCBT) for 12 weeks
Study: 12407614
Drug: Oral amiodarone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amiodarone, 15 mg/kg, 4 hours after arrival in the intensive care unit, followed by 7 mg/kg/d until hospital discharge
Study: 12407614
Drug: Oral amiodarone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amiodarone and Placebo
Study: 9924052
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch for 5 months with nicotine nasal spray for 1 year
Study: 9924052
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch with placebo spray
Study: 7226565
Drug: Naloxone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (4 mg intravenous)
Study: 23764566
Drug: MMT +
Normalized name: RESERVOIR,EXTENDED #MMT-342
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMT + AA (methadone maintenance treatment plus auricular acupuncture)
Study: 23764566
Drug: MMT (methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMT (methadone maintenance treatment)
Study: 21811051
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg α‐lipoic acid (ALA) per day
Study: 16926119
Drug: mini‐BCP supplemented
Approvals — FDA: no, EMA: no, PMDA: no
Description: mini‐BCP supplemented with potassium (initial/others: 15.4/9.8 mEq/L) and magnesium (initial/others: 6.5/4.0 mEq/L)
Study: 16926119
Drug: 4:1‐diluted BCP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4:1‐diluted BCP modified with Buckberg solution
Study: 7598243
Drug: perphenazine 5
Normalized name: perphenazine 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: perphenazine 5 mg
Study: 1964885
Drug: NET-OEN (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: NET-OEN (50 mg) + E2 valerate (5 mg) given every month
Study: 1964885
Drug: NET-OEN (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: NET-OEN (200 mg) given every 2 months
Study: 155389
Drug: Tryptophan-nicotinamide-imipramine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tryptophan-nicotinamide-imipramine combination
Study: 26473975
Drug: Regular intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular intake of carotenoids from supplements and medications in amounts > 6.8 mg/d (upper tertile)
Study: 23647889
Drug: Yoga intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Yoga intervention for 1 hour daily for 3 months along with oral hypoglycemic drugs
Study: 23647889
Drug: Oral hypoglycemic
Normalized name: ORAL HYPOGLYCEMIC AGENTS,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hypoglycemic drugs
Study: 18534438
Drug: Enoxaparin 30
Normalized name: ENOXAPARIN 30MG/0.3ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 30 mg SC BID
Study: 16887327
Drug: Drospirenone containing
Normalized name: Drospirenone
DrugBank: Drospirenone (DB01395)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Drospirenone containing oral contraceptive pill (Yasmin)
Study: 15083986
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (beclomethasone metered-dose inhaler, tapering 4-week course)
Study: 9496526
Drug: Famotidine 20
Normalized name: famotidine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 20 mg intravenously
Study: 2647270
Drug: desipramine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: desipramine (150 mg/day)
Study: 30159779
Drug: DC vaccine
Normalized name: Recombinant chimeric COVID-19 DC vaccine
DrugBank: Dendritic cells vaccine (DB15803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DC vaccine (DCV)